The study showed that, with a metabolic inhibitor, there was no worsening of this QT prolongation with ziprasidone. Moreover, with a very large clinical database, including several cases of overdose with

QT monitoring, showed no increased incidence of adverse events, even all-cause mortality. The increases in QT length are mild and no increase in overall mortality with drug use has been shown. Consequently, despite the QT prolongation, no adverse cardiac Inhibitors,research,lifescience,medical events have been linked to ziprasidone. Thus, the drug has been approved by the FDA with minimal restriction and is being successfully marketed. Its freedom from weight gain as a side effect and its potential for antidepressant actions Inhibitors,research,lifescience,medical due to its reuptake protein blockade should be advantageous for this antipsychotic. Pipeline compounds and novel approaches Many antipsychotic drugs remain in development. Some are pharmacologically similar to current compounds, being potent D2 dopamine and 5-HT2 serotonin receptor antagonists. Despite pharmacological

Inhibitors,research,lifescience,medical similarities, clinical activity differences in efficacy and particularly in side-effect profiles do become apparent with clinical use. Consequently, there still exists room for new or second-generation antipsychotic drug development. However, drugs acting through novel mechanisms to produce a putative antipsychotic action are also being developed and tested. Aripiprazole (a partial dopamine agonist) has been shown to have equivalent efficacy to other antipsychotics and has a more benign side-effect profile than D2 blockers. Iloperidone and sertindole are being prepared for regulatory review. OSU6162 and ACR-16 are Inhibitors,research,lifescience,medical two chemical congeners of each other developed by Arvid

Carlsson and called dopaminergic “stabilizers” because they reduce dopaminergic function when elevated and Inhibitors,research,lifescience,medical elevate dopaminergic function in hypodopamine situations. Moreover, in some categories (glutamatergic drugs, nicotinic agonists, muscarinic-1 antagonists, and metabotropic agents), glutamatergic antipsychotic drug strategies are being subjected to evaluation first in animal models, and then in human studies. Clinicians look forward to having novel antipsychotics potentially targeted at disease pathophysiology. Summary and conclusions The state of therapeutic agents for psychosis is broad today and rather full of opportunity for ADP ribosylation factor patients. Whereas there was a long “dry” period in drug development for psychosis throughout, the whole of the 1980s, histone deacetylase activity research and development laboratories have turned their attention to entirely more creative antipsychotic strategies. Suddenly, a wave of new second-generation drugs were able to stand up to clinical development and now clinicians have several at least equally efficacious treatments with far fewer side effects.